Galena Biopharma to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum
May 24 2016 - 7:05AM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of targeted
oncology therapeutics that address major unmet medical needs, today
announced that Mark W. Schwartz, Ph.D., President and Chief
Executive Officer will present a corporate update at the Sachs
Associates 2nd Annual Immuno-Oncology BD&L and Investment
Forum. The presentation will take place on Friday, June 3, 2016 at
12:40 p.m. CT at the Hyatt Chicago Magnificent Mile Hotel in
Chicago, IL.
The presentation will be webcast and available on the Investors
section of the Company's website at
http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s
development portfolio is focused primarily on addressing the
rapidly growing patient populations of cancer survivors by
harnessing the power of the immune system to prevent cancer
recurrence. The Company’s pipeline consists of multiple mid- to
late-stage clinical assets, including novel cancer immunotherapy
programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax
is currently in a pivotal, Phase 3 breast cancer clinical trial
with several concurrent Phase 2 trials ongoing both as a single
agent and in combination with other therapies. GALE-301 is in a
Phase 2a clinical trial in ovarian and endometrial cancer and in a
Phase 1b given sequentially with GALE-302. For more
information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024